Showing 180 results

Filters Content type: News, Editors' picks, About HIV Topic: Injectable & long-acting PrEP

The antiretroviral drug cabotegavir, administered every eight weeks as an injection, has been shown to be safe and effective in preventing HIV infection in men who have sex with men. Studies in women are ongoing and scientists are also working on a long-acting PrEP implant.

PrEP

Uganda moves forward on PrEP vaginal ring and injection

Editor's pick
Be In The Know
20 December 2022
Injectable & long-acting PrEP

HIVMA welcomes the U.S. Preventive Services Task Force Release of Updated PrEP Rating

Editor's pick
HIV Medicine Association
19 December 2022
PrEP policies & guidelines

PrEP4ALL Applauds The Updated USPSTF Grading Adding Long-Acting PrEP, But Demands Gov’t Action to Ensure Access

Editor's pick
PrEP4All
13 December 2022
Injectable & long-acting PrEP

CAB-LA's Full Potential for HIV Prevention Hits Snags

Editor's pick
Medscape (requires free registration)
13 December 2022
Injectable & long-acting PrEP

Significant milestone for HIV prevention in Sub-Saharan Africa as South Africa grants regulatory approval for Apretude

Editor's pick
ViiV press release
1 December 2022
Injectable & long-acting PrEP

If the price is right: The anti-HIV jab could be in South African clinics by August 2023

Editor's pick
Bhekisisa
1 December 2022
Pharmaceutical industry

Injections against HIV could be manufactured locally and cheaply, says Aspen Pharmacare

Editor's pick
GroundUp
1 December 2022
Injectable & long-acting PrEP

MSF: ViiV must make groundbreaking HIV prevention injection affordable and available

Editor's pick
MSF
29 November 2022
Injectable & long-acting PrEP

Delays in global, affordable access to long-acting, injectable HIV medicines would cost lives, say AIDS campaigners

Editor's pick
UNAIDS
17 November 2022
PrEP programmes & uptake

South Africa to begin piloting injectable PrEP in early 2023

News
7 November 2022
PrEP

PrEP options Video

October 2022
Injectable & long-acting PrEP

European Medicines Agency validates ViiV Healthcare’s marketing authorisation application for cabotegravir long-acting injectable for HIV Prevention

Editor's pick
ViiV press release
28 October 2022
Injectable & long-acting PrEP

Zimbabwe is the first county in Africa to announce regulatory approval for long-acting injectable cabotegravir for HIV prevention

Editor's pick
World Health Organization
18 October 2022
New & experimental HIV treatments

Merck restarts islatravir HIV treatment studies, but abandons monthly PrEP

News
23 September 2022
Transmission & prevention

aidsmapLIVE: HIV prevention Video

September 2022
Transgender people

Injectable PrEP is just as effective for transgender women as it is for gay men, study analysis finds

News
11 August 2022
Injectable & long-acting PrEP

Preventive HIV drug shows urgent need for transparency on pricing

Editor's pick
Nature (editorial)
10 August 2022
Global health initiatives

aidsmapLIVE: AIDS 2022 special Video

August 2022
Injectable & long-acting PrEP

Injectable PrEP can only cost a little more than oral PrEP if it is to be cost-effective, South African study finds

News
3 August 2022
Access to healthcare

Just six injections a year can prevent HIV: here’s what it will take for the world to afford them

News
2 August 2022
Generic medicines

ViiV Healthcare to allow 90 countries to access generic versions of HIV prevention shot

News
28 July 2022
Injectable & long-acting PrEP

ViiV Healthcare and the Medicines Patent Pool sign new voluntary licensing agreement to expand access to innovative long-acting HIV prevention medicine

Editor's pick
Medicines Patent Pool
28 July 2022
Injectable & long-acting PrEP

UNAIDS welcomes ViiV’s agreement to enable generic production of long acting PrEP to 90 countries

Editor's pick
UNAIDS
28 July 2022
Injectable & long-acting PrEP

Injectable and long-acting PrEP A research briefing

About HIV
July 2022